Lorna Barte, MD
Psychiatry · Camarillo, CANPI 1154376762
Payments from drug & device makers
Across 1,515 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$4K
- AbbVie$3K
- Neurocrine Biosciences, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Vanda Pharmaceuticals Inc.$2K
- plus $8K from 23 others
What the payments were for
- Food & beverage$25,06899%
- Education$1541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 242 | $4,182 |
| AbbVie(2 entities) | 220 | $3,206 |
| Neurocrine Biosciences, Inc. | 169 | $3,021 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 175 | $2,832 |
| Teva Pharmaceuticals USA, Inc. | 101 | $1,776 |
| Vanda Pharmaceuticals Inc. | 96 | $1,728 |
| Takeda Pharmaceuticals U.S.A., Inc. | 111 | $1,330 |
| Otsuka America Pharmaceutical, Inc. | 72 | $1,174 |
| Alkermes, Inc. | 51 | $947 |
| Axsome Therapeutics, Inc. | 34 | $636 |
| Indivior Inc. | 24 | $549 |
| Almatica Pharma LLC | 23 | $464 |
| E.r. Squibb & Sons, L.L.C. | 21 | $456 |
| Sunovion Pharmaceuticals Inc. | 37 | $404 |
| Azurity Pharmaceuticals, Inc. | 16 | $319 |
| Bausch Health US, LLC | 15 | $314 |
| Avanir Pharmaceuticals, Inc. | 25 | $281 |
| Corium, LLC | 14 | $260 |
| Johnson & Johnson | 10 | $228 |
| Sage Therapeutics, LLC | 11 | $221 |
| Eisai Inc. | 13 | $210 |
| Idorsia Pharmaceuticals US Inc | 9 | $195 |
| Merck | 9 | $172 |
| Arbor Pharmaceuticals, Inc. | 5 | $94 |
| Noven Therapeutics, LLC | 4 | $86 |
| Jazz Pharmaceuticals Inc. | 4 | $58 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Tonix Medicines, Inc. | 1 | $15 |
How this compares
$25,221 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 456 | $737,044 |
| IngrezzaValbenazine Tosylate | 78 | $587,427 |
| AustedoDeutetrabenazine | 111 | $583,153 |
| Abilify MaintenaAripiprazole | 158 | $412,133 |
| AristadaAripiprazole Lauroxil | 112 | $314,187 |
| RexultiBrexpiprazole | 122 | $197,546 |
| FanaptIloperidone | 75 | $120,929 |
| VraylarCariprazine Hcl | 67 | $102,442 |
| Invega SustennaPaliperidone Palmitate | 25 | $85,573 |
| BelsomraSuvorexant | 97 | $55,784 |
| TrintellixVortioxetine Hydrobromide | 84 | $53,113 |
| Asenapine Maleate | 203 | $46,742 |
| LybalviOlanzapine/Samidorphan Malate | 23 | $38,217 |
| PerserisRisperidone | 13 | $37,347 |
| UzedyRisperidone | 22 | $33,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,832 | $737,044456 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $1,776 | $616,300133 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,174 | $609,679280 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $3,021 | $587,42778 claims |
| Alkermes, Inc.Aristada, Lybalvi | $947 | $352,404135 claims |
| AbbVieVraylar, Fetzima, Linzess | $3,206 | $126,572117 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,728 | $120,92975 claims |
| Johnson & JohnsonInvega Sustenna | $228 | $85,57325 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,330 | $75,185129 claims |
| MerckBelsomra | $172 | $55,78497 claims |
| Indivior Inc.Perseris | $549 | $37,34713 claims |
| Axsome Therapeutics, Inc.Auvelity | $636 | $28,25423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Camarillo
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.